RU2456014C2 - ANTIMELANCHOLIC MEDICINE PREPARED WITH JUJUBA cAMP MATERIALS - Google Patents

Abstract

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a medicine for treating depression. The oral medicine for treating depression prepared from a jujuba extract containing jujube cyclic adenosine monophosphate (jujuba cAMP) and an additional ingredient taken from a group consisting of a pharmaceutically acceptable carrier, an additive, an adjuvant and combination thereof. A method for preparing jujube cyclic adenosine monophosphate (jujuba cAMP) taken as an ingredient of the medicine for treating depression, involving the stages: (a) jujube extraction in water and alcohol to produce a primary extract, (b) primary extract purification to produce a secondary extract wherein the jujuba cAMP concentration in the secondary extract is higher than that in the primary extract wherein the stage (b) is performed by jujuba cAMP chromatography of the primary extract with the use of macroporous resins bound with an aldehyde group.

EFFECT: medicine is effective for treating depression, has no side effects.

16 cl, 7 dwg, 2 tbl, 9 ex

Description

Field of Invention

[0001] This invention relates to a medicament or wellness food product derived from cyclic adenosine monophosphate (trans. CAMP) jujuba (jujuba cAMP) for the treatment of depression (melancholy). In addition, this invention relates to a method for producing a medicament or wellness product from jujuba cAMP material for the treatment of depression.

BACKGROUND OF THE INVENTION

[0002] Depression is a common disease. According to statistics, about 25% of women in the world experienced depression in their lives and about 10% of men experienced depression (link to Modern Psychology, written by Ch'un-Hsing Chang). The World Health Organization (WHO) published "The incidence of depression in the world is approximately 11%. Currently, there are approximately 340 million patients with psychological depression and the number is increasing. The study found that depression will increase to become the second most common disease in the world from the present for the next 20 years. "

[0003] Currently, the main antidepressant drugs are Prozac, Paxil and Zoloft, etc., which relate to selective serotonin reuptake inhibitors (SSRI), serotonin reuptake inhibitors, norepinephrine (SNRI) and norepinephrine reuptake inhibitors and dopamine (NDRI), which inhibits the uptake of neurotransmitters such as 5-hydroxytryptamine (5-HT), norepinephrine (NE) and dopamine (DA). The mechanism by which these drugs function is to increase the level of human neurotransmitters, such as 5-HT, to reduce and alleviate the symptoms of depression.

[0004] However, these antidepressant drugs have various side effects with varying severity, such as increased suicide, headache, dizziness, vertigo, insomnia, hypersomnia, tinnitus, thirst, aversion to food, orexia, increased body weight, high blood pressure, indigestion, regurgitation with nausea, vomiting, dyspepsia, diarrhea, constipation, leg pain, skin rash, chills, cramps, hyperhidrosis, edema, sex drive and impotence, etc. In recent years, drugs Arata for depression, such as Prozac, etc., has become a serious social problem. In 2004, the U.S. Food and Drug Administration (FDA) further requested pharmaceutical companies to revise medical use instructions to clearly indicate side effects and warnings on 32 of the most important antidepressant drugs on the market and focused the attention of doctors and nurses on that these drugs can increase suicide in children and adolescents. In 1996, it was even discovered that among 32 antidepressants, Paxil is dangerous and has been repeatedly withdrawn from the market since 2001. In June 2004, the New York State Attorney General accused GlaxoSmithKline, UK of fraudulently hiding a report on a study of the link between paxil and "increased risk of suicidal behavior and adolescent tendencies." In the light of the current situation, the search for a new generation of drugs with fewer side effects and more pronounced / strong antidepressant qualities has become the focus of attention of the entire pharmaceutical world.

[0005] Therefore, an attempt was made by the authors of the application to consider the above situation, found in the prior art.

SUMMARY OF THE INVENTION

[0006] An object of the present invention is to provide a medicament or wellness product derived from a material containing jujuba cAMP for treating depression to overcome a deficiency in existing technology. In particular, the invention provides new technological schemes that eliminate the side effects of an existing antidepressant drug.

[0007] Another objective of the present invention is to provide a method for producing a drug or a health food product from a material containing jujuba cAMP for the treatment of depression.

[0008] The approval scheme of a pharmaceutical preparation of the present invention is a result undertaken by the inventor. The resolution scheme combines the theory of modern medicine and pharmacology. In particular, the resolution scheme combines the field of research on signaling via the signaling pathway of adenylate cyclase (AC) - cyclic adenosine monophosphate (cAMP) (trans., CAMP) - and not only the cAMP-induced transcription process. The author of the invention attempts to study traditional plant materials for the treatment of depression. After many animal experiments, the study proved that jujuba cAMP, being an exogenous non-hydrolyzable cAMP, can participate in the cAMP movement in the body and mimic the enzymatic function to increase cAMP in cells, thus achieving an antidepressant effect. jujuba cAMP is extracted from the everyday jujuba fruit. In the long history of humankind's daily consumption of jujuba in the form of fruit and in the form of materials of herbal medicines of Chinese origin, there was no case of a harmful reaction associated with the intake of jujub, unlike the existing antidepressant drugs, which have many undesirable side effects. After the inventor has extracted jujuba water containing a trace amount of jujuba cAMP (approximately one ten thousandth), the inventor further purifies the aqueous jujub extract to jujub extract containing 1% jujuba cAMP. Thus, the processed jujuba extract is tested in animal experiments for the antiexperimental function of depression, and the result demonstrates that the jujub extract has an antiexperimental function of depression. On the contrary, the aqueous jujuba extract, which was not further purified to increase the jujuba cAMP concentration, along with the trace amount of jujuba cAMP, does not have a noticeable antiexperimental function of depression with a normal dose of the drug acting in an experiment on animals tested for the antiexperimental function of depression. Thus, the inventor presents a new technological scheme for the manufacture of a medicinal product from the source material of jujuba cAMP for the treatment of depression, to improve the failure in the art.

[0009] cAMP jujuba:

[0010] Source: dried ripened fruit of Zizyphus jujuba Mill.

[0011] Synonym: 3 ', 5'-cyclic adenosine monophosphate or 3', 5'-cyclic phosphate.

[0012] English name: cyclic adenosine-3 ', 5'-monophosphate.

[0013] Molecular formula and relative molecular weight: C ₁₀ H ₁₃ N ₅ O ₆ P · H ₂ O and 347.23, respectively.

[0014] Biological activity: The activity of cAMP-like material in jujuba is similar to that of cAMP. Moreover, cAMP, being an exogenous non-hydrolyzable cAMP, can mimic the function of the enzyme to increase cAMP in cells.

[0015] Structural formula:

[0016] In accordance with one aspect of the present invention, there is provided a medicament for treating depression. The drug includes jujuba cAMP.

[0017] Preferably, the medicament is formulated as an oral medicament.

[0018] Preferably, the medicament is in a dosage form, being one selected from the group consisting of a tablet, capsule, powder, dragee, powder, solution, microcapsule, suspension, emulsion, particle, drip, and bead.

[0019] Preferably, the dosage form is a first oral dosage form for once-daily administration and contains from 0.003 mg to 0.3 mg jujuba cAMP. Preferably, the first oral dosage form contains from 0.01 mg to 0.25 mg of jujuba cAMP.

[0020] Preferably, the dosage form is a second oral dosage form for administration twice a day and contains from 0.002 mg to 0.2 mg jujuba cAMP. Preferably, the second oral dosage form contains from 0.005 mg to 0.12 mg of jujuba cAMP.

[0021] Preferably, the dosage form is a third oral dosage form for administration three times a day and contains from 0.001 mg to 0.1 mg jujuba cAMP. Preferably, the third oral dosage form contains from 0.003 mg to 0.08 mg of jujuba cAMP.

[0022] Preferably, the dosage form is a fourth oral dosage form for administration four times a day and contains from 0.0008 mg to 0.06 mg of jujuba cAMP. Preferably, the fourth oral dosage form contains from 0.002 mg to 0.04 mg jujuba cAMP.

[0023] Preferably, the medicament according to claim 1 further includes at least one pharmacologically acceptable carrier and additive.

[0024] Preferably, the medicament is formulated as a health product or food supplement.

[0025] Preferably, jujuba cAMP is extracted from jujub.

[0026] Preferably, the jujuba is extracted to obtain a primary extract having a primary concentration of jujuba cAMP, the primary extract is further extracted to obtain a secondary extract having a secondary concentration of jujuba cAMP, the secondary concentration of jujuba cAMP is higher than the primary concentration of jujuba cAMP, and the secondary extract is starting material in a given drug.

[0027] In accordance with another aspect of the present invention, there is provided a method for producing jujuba cAMP of a medicament for the treatment of depression. The preparation method comprises the steps of: (a) extracting jujuba to obtain a primary extract having a primary concentration of jujuba cAMP; and (b) purifying the primary extract to obtain a secondary extract having a secondary concentration of jujuba cAMP. The secondary concentration of jujuba cAMP is higher than the primary jujuba cAMP concentration.

[0028] Preferably, step (b) is carried out by chromatography of the primary extract using a macroporous resin with an attached aldehyde group.

[0029] Preferably, step (b) further comprises the steps of: (b1) chromatographing the primary extract using a macroporous OU-2 resin with an attached aldehyde group; and (b2) chromatography the primary extract using a macroporous resin ME-2 with an associated aldehyde group.

[0030] In accordance with another aspect of the present invention, a method for producing jujuba cAMP is provided. The method includes the steps of: (a) extracting jujub to obtain a primary extract; and (b) chromatography the primary extract using a macroporous resin having an aldehyde group attached thereto.

[0031] The above objectives and advantages of the present invention will become fully apparent to those of ordinary skill in the art after reviewing the following detailed descriptions and the accompanying drawings, in which:

Brief Description of the Drawings

[0032] FIG. 1 is a flowchart showing a method for producing a medicament in accordance with a first preferred embodiment of the present invention.

[0033] FIG. 2 is a flowchart showing a method for producing a medicament in accordance with a second preferred embodiment of the present invention.

[0034] FIG. 3 is a flowchart showing a method for producing a medicament in accordance with a third preferred embodiment of the present invention.

[0035] FIG. 4 is a flowchart showing a method for producing a medicament in accordance with a fourth preferred embodiment of the present invention.

[0036] FIG. 5 is a flowchart showing a method for producing a medicament in accordance with a fifth preferred embodiment of the present invention.

[0037] FIG. 6 is a flowchart showing a method for producing a medicament in accordance with a sixth preferred embodiment of the present invention.

[0038] FIG. 7 is a flowchart showing a method for producing a medicament in accordance with a seventh preferred embodiment of the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0039] The present invention will now be described more specifically with reference to the following options. It should be noted that the following descriptions of the preferred variants of the present invention are presented here only for purposes of illustration and description; they are not intended to be exhaustive or limited to the exact form disclosed.

[0040] In order to accomplish the purpose of the present invention, the technological schemes of the present invention are specifically provided as set forth below.

Example 1

[0041] The oral drug of the present invention for treating depression is made from a material, including jujuba cAMP.

Example 2

[0042] The starting material, including jujuba cAMP, is prepared in the form of any pharmacologically standard dosage form for the oral administration of the present invention, such as a tablet, capsule, powder, dragee, powder, solution, microcapsule, suspension, emulsion, particle, drip agent and ball, etc. to treat depression.

Example 3

[0043] The pharmaceutical composition of this invention is made from starting material, including 0.003 ~ 0.3 mg jujuba cAMP in the form of a once-daily dosage form. Preferably, the pharmaceutical composition of the present invention is made from a starting material, including 0.01 ~ 0.25 mg jujuba cAMP in the form of a once-daily dosage form.

Example 4

[0044] The pharmaceutical composition of this invention is made from a starting material, including 0.002 ~ 0.2 mg jujuba cAMP in the form of a dosage form for administration twice a day. Preferably, the pharmaceutical composition of the present invention is made from a starting material, including 0.005 ~ 0.12 mg jujuba cAMP in the form of a dosage form for administration twice a day.

Example 5

[0045] The pharmaceutical composition of the present invention is made from a starting material, including 0.001 ~ 0.1 mg jujuba cAMP in the form of a dosage form for administration three times a day. Preferably, the pharmaceutical composition of this invention is made from starting material, including 0.003 ~ 0.08 mg jujuba cAMP in the form of a dosage form for administration three times a day.

Example 6

[0046] The pharmaceutical composition of this invention is made from a starting material, including 0.0008 ~ 0.06 mg jujuba cAMP in the form of a dosage form for administration four times a day. Preferably, the pharmaceutical composition of the present invention is made from a starting material, including 0.002 ~ 0.04 mg jujuba cAMP in the form of a dosage form for administration four times a day.

Example 7

[0047] After grinding the jujuba, the crushed jujuba is soaked in water at room temperature and then digested and precipitated with alcohol to obtain a jujuba extract, which is further absorbed, sequentially separated on OU-2 and ME-2 macroporous resins and dried. In conclusion, a jujub extract is obtained containing a high concentration of jujuba cAMP, which is the starting material for the preparation of the pharmaceutical composition of the present invention.

Example 8

[0048] A medicament for oral administration of the present invention may include pharmacologically acceptable carriers, additives and their composition.

Example 9

[0049] The oral medicament of the present invention can be further formulated as a health product and nutritional supplement.

[0050] In order to achieve the objective of the present invention, methods for preparing a pharmaceutical composition are described as follows.

Method 1

[0051] In accordance with the Pharmaceutical Manufacturing Standard of Good Manufacturing Practices (GMP), an oral medicament of the present invention for treating depression is made from a starting material, including jujuba cAMP.

Method 2

[0052] In accordance with the GMP pharmaceutical production standard, the starting material, including jujuba cAMP, is formulated as any pharmacologically accepted oral drug of the invention, such as a tablet, capsule, powder, dragee, powder, solution, microcapsule, suspension , emulsion, particle, drip and ball, etc., for the treatment of depression.

Method 3

[0053] In accordance with the pharmaceutical standard for the production of GMP, the drug of this invention is made from the starting material, including 0.003 ~ 0.3 mg of jujuba cAMP in the form of a once-daily dosage form. Preferably, the medicament of the present invention is made from a starting material, including 0.01 ~ 0.25 mg jujuba cAMP in the form of a once-daily dosage form.

Method 4

[0054] According to the GMP pharmaceutical production standard, the drug of the present invention is made from the starting material, including 0.002 ~ 0.2 mg of jujuba cAMP in the form of a dosage form for administration twice a day. Preferably, the medicament of this invention is made from a starting material, including 0.005 ~ 0.12 mg jujuba cAMP in the form of a dosage form for administration twice a day.

Method 5

[0055] According to the GMP pharmaceutical production standard, the drug of the present invention is made from the starting material, including 0.001 ~ 0.1 mg jujuba cAMP in the form of a dosage form for administration three times a day. Preferably, the medicament of the present invention is made from a starting material, including 0.003 ~ 0.08 mg of jujuba cAMP in the form of a dosage form for administration three times a day.

Method 6

[0056] According to the GMP pharmaceutical production standard, the drug of the present invention is made from the starting material, including 0.0008 ~ 0.06 mg jujuba cAMP in the form of a dosage form for administration four times a day. Preferably, the medicament of the present invention is made from a starting material, including 0.002 ~ 0.04 mg jujuba cAMP in the form of a dosage form for administration four times a day.

Method 7

[0057] In accordance with the GMP pharmaceutical production standard, after the jujuba is ground, the ground jujuba is soaked in water at room temperature and then the soaked jujuba is extracted by digestion and precipitation with alcohol to obtain the jujuba extract, which is further absorbed, sequentially separated into OU-2 and ME- macroporous resins 2 and dried. In conclusion, a jujub extract is obtained containing a high concentration of jujuba cAMP, which is the starting material for the preparation of the pharmaceutical composition of the present invention.

Method 8

[0058] According to the GMP pharmaceutical production standard, the oral medicament of the present invention may include pharmacologically acceptable carriers, additives and their composition.

Method 9

[0059] According to the GMP pharmaceutical production standard, the oral medicament of the present invention can be further formulated as a health product and nutritional supplement.

Preferred Embodiment

[0060] The invention is further illustrated, as set forth below, by a combination of figures and preferred embodiments of the invention.

Option 1

[0061] Please refer to FIG. 1, which is a flowchart showing a method for producing a medicament in accordance with a first preferred embodiment of the present invention. 1, in accordance with the GMP pharmaceutical production standard, 30 g of the obtained jujuba extract having 1% jujuba cAMP are the starting material (step 101). Two hundred seventy (270) g of adjuvant and excipient (such as starch, lactose, silicon dioxide and magnesium stearate, etc.) are added to make a tablet dosage form (10,000 tablets, 30 mg / tablet and 0.03 mg jujuba cAMP per tablet) a medicament for oral use or a wellness product of the present invention for the treatment of depression (steps 102 and 103).

Option 2

[0062] Please refer to FIG. 2, which is a flowchart showing a method for producing a medicament in accordance with a second preferred embodiment of the present invention. In figure 2, in accordance with the pharmaceutical standard for the production of GMP, 30 g of the obtained jujuba extract having 1% jujuba cAMP are the starting material (step 201). Four hundred and twenty (420) g of adjuvant and excipient (such as starch, lactose, silicon dioxide and magnesium stearate, etc.) are added to make a tablet dosage form (15,000 tablets, 30 mg / tablet and 0.02 mg jujuba cAMP per tablet) a medicament for oral use or a wellness product of the present invention for the treatment of depression (steps 202 and 203).

Option 3

[0063] Please refer to FIG. 3, which is a flowchart showing a method for producing a medicament in accordance with a third preferred embodiment of the present invention. In figure 3, in accordance with the pharmaceutical standard for the production of GMP, 50 g of the obtained jujuba extract having 1% jujuba cAMP are the starting material (step 301). Two hundred and fifty (250) g of adjuvant and excipient (such as starch, lactose, silicon dioxide and magnesium stearate, etc.) are added to prepare a tablet dosage form (10,000 tablets, 30 mg / tablet and 0.05 mg jujuba cAMP per tablet) a medicament for oral use or a wellness product of the present invention for the treatment of depression (steps 302 and 303).

Option 4

[0064] Please refer to FIG. 4, which is a flowchart showing a method for producing a medicament in accordance with a fourth preferred embodiment of the present invention. In FIG. 4, in accordance with the GMP pharmaceutical production standard, 30 g of the obtained jujuba extract having 1% jujuba cAMP are the starting material (step 401). Two hundred ten (210) g of adjuvant and excipient (such as starch, lactose, silicon dioxide and magnesium stearate, etc.) are added to make a tablet dosage form (12000 tablets, 20 mg / tablet and 0.25 mg jujuba cAMP per tablet) a medicament for oral use or a wellness product of the present invention for the treatment of depression (steps 402 and 403).

Option 5

[0065] Please refer to FIG. 5, which is a flowchart showing a method for producing a medicament in accordance with a fifth preferred embodiment of the present invention. In FIG. 5, in accordance with the GMP pharmaceutical production standard, 17 g of the obtained jujuba extract having 1% jujuba cAMP are the starting material (step 501). One hundred eighty-three (183) g of adjuvant and excipient (such as starch, lactose, silicon dioxide and magnesium stearate, etc.) are added to make a tablet dosage form (10,000 tablets, 20 mg / tablet and 0.17 mg jujuba cAMP per tablet) of a medicament for oral use or a wellness product of the present invention for the treatment of depression (steps 502 and 503).

Option 6

[0066] Please refer to FIG. 6, which is a flowchart showing a method for producing a medicament in accordance with a sixth preferred embodiment of the present invention. 6, in accordance with the GMP pharmaceutical production standard, 13 g of the obtained jujuba extract having 1% jujuba cAMP are the starting material (step 601). One hundred eighty seven (187) g of adjuvant and excipient (such as starch, lactose, silicon dioxide and magnesium stearate, etc.) are added to make a tablet dosage form (10,000 tablets, 20 mg / tablet and 0.013 mg jujuba cAMP per tablet ) a medicament for oral use or a wellness product of the present invention for the treatment of depression (stages 602 and 603).

Option 7

[0067] Please refer to FIG. 7, which is a flowchart showing a method for producing a medicament in accordance with a seventh preferred embodiment of the present invention. 7, in accordance with the GMP pharmaceutical production standard, after grinding 10 kg of jujuba (step 701), the ground jujuba is soaked in water at room temperature and then the soaked jujuba is extracted by boiling and precipitating with alcohol to obtain a jujuba extract, which is further absorbed and separated into macroporous resins OU-2 and ME-2 are sequentially and dried to obtain 30 g of jujuba extract having jujuba cAMP (step 702). Jujuba extract having 1% (300 mg) jujuba cAMP is measured by high performance liquid chromatography (HPLC) for the manufacture of a medicament for oral administration or a wellness product of the present invention for the treatment of depression (step 703).

Experiment 1: Effect of Option 3 in a Tail Suspension Experiment

[0068] 1.1 Experimental animals: ICR mice, males, body weight 22.0 ± 2 g, secondary, provided by the Department of Experimental Animal Science of Capital Medical University, Beijing.

[0069] 1.2 Experimental Medicines: Option 3 drug provided by Beijing Wonner Biotech. Ltd. Co., and paroxetine (paxil) is a product of Zhong Mei Tianjin Smith Kline pharmaceuticals Co. Ltd:

[0070] 1.3 Experimental equipment: stopwatch.

[0071] 1.4 Dose designs: 1. High dose of option 3 (5 mg / kg / day); 2. The average dose of option 3 (2.5 mg / kg / day); and 3. Low dose of option 3 (1.25 mg / kg / day).

[0072] 1.5 Experimental method and result:

[0073] 1.5.1 Grouping and drug administration: Mice are randomly divided into groups, and each group contains 10 mice. 1. A high dose of option 3 (5 mg / kg, orally (P.O.), was administered for 7 days); 2. The average dose of option 3 (2.5 mg / kg, P.O., was administered over 7 days); 3. a low dose of option 3 (1.25 mg / kg, P.O., administered within 7 days); 4. paroxetine (3 mg / kg, P.O., administered over 7 days); and 5. saline solution (P.O.). 1 hour after the last administration of the drug, an experiment was performed by hanging the mouse by the tail.

[0074] 1.5.2 Experimental method: The tail of the mouse (1 cm to the tip of the tail) is glued with adhesive tape to a wooden plank 5 cm higher than the platform and suspended for 6 minutes. Record the time of immobility of the mouse for at least 5 minutes.

и результат эксперимента вычисляют в виде дисперсионного анализа (ANOVA) с помощью пакета программ обработки статистических данных SPSS 11.[0075] 1.5.3 Statistical calculation: Experimental data are presented as

and the result of the experiment is calculated in the form of analysis of variance (ANOVA) using the statistical processing software package SPSS 11.

[0076] 1.5.4 Experiment result: see table 1.

Table 1 The effect of option 3 on the time of immobility of the mouse Group Number of animals Immobility time (seconds) Saline solution (control) 10 122.18 ± 45.78 Paroxetine 10 67.59 ± 39.09 ** High Dose Option 3 10 75.13 ± 38.26 ** The average dose of option 3 10 86.80 ± 48.08 * Low Dose Option 3 10 102.36 ± 13.68 Compared to the control group: * P <0.05 and ** P <0.01.

[0077] Conclusion: According to the above experiment, it can be found that the high and medium doses of Embodiment 3 of the present invention and paroxetine all reduce the immobility time after hanging the mouse by the tail. The differences are significant compared with the group of saline solution (control). Thus, embodiment 3 of the present invention, as having the antiexperimental function of depression, can be extrapolated.

Experiment 2: The effect of option 3 in the experiment forced swimming mice

[0078] 2.1 Experimental animals: ICR mice, males, body weight 22.0 ± 2 g, secondary, provided by the Department of Experimental Animals of the Capital Medical University, Beijing.

[0079] 2.2 Experimental Medicines: Option 3 drug provided by Beijing Wonner Biotech. Ltd. Co., and paroxetine (paxil) is a product of Zhong Mei Tianjin Smith Kline pharmaceuticals Co. Ltd.

[0080] 2.3 Experimental equipment: stopwatch.

[0081] 2.4 Dose designs: 1. High dose of option 3 (5 mg / kg / day); 2. The average dose of option 3 (2.5 mg / kg / day); and 3. Low dose of option 3 (1.25 mg / kg / day).

[0082] 2.5 Experimental method and result:

[0083] 2.5.1 Grouping and drug administration: Mice are randomly divided into groups, and each group contains 10 mice. 1. A high dose of option 3 (5 mg / kg, orally (P.O.), was administered for 7 days); 2. The average dose of option 3 (2.5 mg / kg, P.O., was administered over 7 days); 3. a low dose of option 3 (1.25 mg / kg, P.O., administered within 7 days); 4. paroxetine (3 mg / kg, P.O., administered over 7 days); and 5. saline solution (P.O.).

[0084] 2.5.2 Experimental method: 1 hour after the last injection of the drug, the mouse is placed in water at 25 ° C in a glass tank having a water depth of 10 cm and a diameter of 14 cm. The total time of immobility of the mouse in water during the last 5 is recorded. minutes.

и результат эксперимента вычисляют в виде ANOVA с помощью пакета программ обработки статистических данных SPSS 11.[0085] 2.5.3 Statistical calculation: Experimental data are presented as

and the result of the experiment is calculated as ANOVA using the SPSS 11 statistical processing software package.

[0086] 2.5.4 Experiment result: see table 2.

table 2 The result of the immobility time in the experiment of forced swimming of mice Group Number of animals Stillness time (seconds) Saline solution (control) 10 127.53 ± 41.80 Paroxetine 10 83.42 ± 40.71 * High Dose Option 3 10 80.39 ± 40.89 * The average dose of option 3 10 87.60 ± 43.42 Low Dose Option 3 10 91.05 ± 47.21

Compared to the control group: * P <0.05 and ** P <0.01.

[0087] Conclusion: According to the above experiment, it can be found that high doses of option 3 of the present invention and paroxetine all reduce the immobility time in the mouse forced swimming test. Thus, embodiment 3 of the present invention, as having the antiexperimental function of depression, can be extrapolated.

Industrial suitability

[0088] The scope of the medicament for oral administration of the present invention for the treatment of depression is that:

[0089] 1) the oral medicament described in this invention for the treatment of depression may include pharmacologically acceptable additives;

[0090] 2) the oral medication described in this invention for the treatment of depression can be made in the form of known dosage forms, such as a powder, capsule and tablet, etc .; and

[0091] 3) the oral medicament described in this invention for treating depression can be formulated as a therapeutic nutrition for treating depression.

[0092] While the invention has been described in the context of what is currently believed to be the most practical and preferred embodiments of the invention, it should be understood that the invention should not be limited by the disclosed embodiments. On the contrary, the invention is intended to cover various modifications and similar compositions included within the spirit and scope of the appended claims, which should be consistent with the broadest interpretation so as to encompass all such modifications and similar structures.

Claims (16)

1. An oral medication for the treatment of depression, which consists of a jujub extract containing cyclic jujub adenosine monophosphate (jujuba cAMP), and additionally a component taken from the group consisting of a pharmaceutically acceptable carrier, additive, adjuvant, excipient, and combinations thereof. 2. The drug according to claim 1, where the material is a secondary extract obtained by extraction of jujuba to obtain a primary extract first, where the concentration of jujuba cAMP of the jujuba secondary extract is higher than the concentration of jujuba cAMP of the jujuba primary extract. 3. The drug according to claim 1, having a dosage form, being one selected from the group consisting of tablets, capsules, powder, dragees, powders, solutions, microcapsules, suspensions, emulsions, particles, droplets and a ball. 4. The drug according to claim 3, where the dosage form is the first dosage form for oral administration for once-daily administration and contains from 0.003 mg to 0.3 mg jujuba cAMP. 5. The drug according to claim 4, where the first dosage form for oral administration contains from 0.01 mg to 0.25 mg of jujuba cAMP. 6. The drug according to claim 3, where the dosage form is a second dosage form for oral administration for administration twice a day and contains from 0.002 mg to 0.2 mg jujuba cAMP. 7. The drug according to claim 6, where the second dosage form for oral administration contains from 0.005 mg to 0.12 mg of jujuba cAMP. 8. The drug according to claim 3, where the dosage form is a third dosage form for oral administration for administration three times a day and contains from 0.001 mg to 0.1 mg jujuba cAMP. 9. The drug of claim 8, where the third dosage form for oral administration contains from 0.003 mg to 0.08 mg of jujuba cAMP. 10. The drug according to claim 3, where the dosage form is a fourth dosage form for oral administration for administration four times a day and contains from 0.0008 mg to 0.06 mg of jujuba cAMP. 11. The drug of claim 10, where the fourth dosage form for oral administration contains from 0.002 mg to 0.04 mg of jujuba cAMP. 12. The drug according to claim 1, in which the filler is selected from the group consisting of starch, lactose, silicon dioxide, magnesium stearate and combinations thereof. 13. The drug according to claim 1, produced in the form of one of the health food product and nutritional supplement. 14. A method of obtaining an extract of cyclic jujuba adenosine monophosphate (jujuba cAMP), which is part of the drug according to claim 1, for the treatment of depression, comprising the steps of:
(a) extracting jujuba with water and alcohol to obtain a primary extract; and
(b) purifying the primary extract to obtain a secondary extract, wherein the concentration of jujuba cAMP of the secondary extract is higher than the concentration of jujuba cAMP of the primary extract,
where step (b) is carried out by chromatography of a jujuba cAMP of a primary extract using a macroporous resin bound to an aldehyde group. 15. The production method according to 14, where stage (b) is carried out by chromatography of a jujuba cAMP of a primary extract using the OU-2 macroporous resin bound to the aldehyde group. 16. The production method of claim 14, wherein step (b) further comprises chromatography of the jujuba cAMP of the primary extract using the ME-2 macroporous resin bonded to the aldehyde group.

Images